Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs

Cancer Science

Volumn 104, Issue 5, 2013, Pages 573-583

  Ogi, Sayaka ^a   Fujita, Hideaki ^a   Kashihara, Masaki ^a   Yamamoto, Chizuko ^a   Sonoda, Kahori ^a   Okamoto, Isamu ^b   Nakagawa, Kazuhiko ^b   Ohdo, Shigehiro ^a   Tanaka, Yoshitaka ^a   Kuwano, Michihiko ^a   Ono, Mayumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALOXISTATIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LEUPEPTIN; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PEPSTATIN; PROTEINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; SORTING NEXIN; SORTING NEXIN 1; SORTING NEXIN 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CANCER; MEMBRANE TRANSPORT; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; LYSOSOMES; MEMBRANE TRANSPORT PROTEINS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SORTING NEXINS;

EID: 84876417682     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12117     Document Type: Article

References (32)

1. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005; 172: 523-9.
2. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
3. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
4. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11.
5. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895-9.
6. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
7. Yano S, Wang W, Li Q et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008; 68: 9479-87.
8. Kurten RC, Cadena DL, Gill GN. Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science 1996; 272: 1008-10.
9. Worby CA, Dixon JE. Sorting out the cellular functions of sorting nexins. Nat Rev Mol Cell Biol 2002; 3: 919-31.
10. Haft CR, de la Luz Sierra M, Barr VA, Haft DH, Taylor SI. Identification of a family of sorting nexin molecules and characterization of their association with receptors. Mol Cell Biol 1998; 18: 7278-87.
11. Griffin CT, Trejo J, Magnuson T. Genetic evidence for a mammalian retromer complex containing sorting nexins 1 and 2. Proc Natl Acad Sci U S A 2005; 102: 15173-7.
12. Cozier GE, Carlton J, McGregor AH et al. The phox homology (PX) domain-dependent, 3-phosphoinositide-mediated association of sorting nexin-1 with an early sorting endosomal compartment is required for its ability to regulate epidermal growth factor receptor degradation. J Biol Chem 2002; 277: 48730-6.
13. Carlton J, Bujny M, Peter BJ et al. Sorting nexin-1 mediates tubular endosome-to-TGN transport through coincidence sensing of high-curvature membranes and 3-phosphoinositides. Curr Biol 2004; 14: 1791-800.
14. Gullapalli A, Garrett TA, Paing MM, Griffin CT, Yang Y, Trejo J. A role for sorting nexin 2 in epidermal growth factor receptor down-regulation: evidence for distinct functions of sorting nexin 1 and 2 in protein trafficking. Mol Biol Cell 2004; 15: 2143-55.
15. Cavet ME, Pang J, Yin G, Berk BC. An epidermal growth factor (EGF)-dependent interaction between GIT1 and sorting nexin 6 promotes degradation of the EGF receptor. FASEB J 2008; 22: 3607-16.
16. Schaaf CP, Benzing J, Schmitt T et al. Novel interaction partners of the TPR/MET tyrosine kinase. FASEB J 2005; 19: 267-9.
17. Ono M, Hirata A, Kometani T et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004; 3: 465-72.
18. Yoshida T, Okamoto I, Okamoto W et al. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci 2010; 101: 167-72.
19. Hammond DE, Urbé S, Vande Woude GF, Clague MJ. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 2001; 20: 2761-70.
20. Kermorgant S, Zicha D, Parker PJ. Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J Biol Chem 2003; 278: 28921-9.
21. Foveau B, Ancot F, Leroy C et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 2009; 20: 2495-507.
22. Carlton JG, Bujny MV, Peter BJ et al. Sorting nexin-2 is associated with tubular elements of the early endosome, but is not essential for retromer-mediated endosome-to-TGN transport. J Cell Sci 2005; 118: 4527-39.
23. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: 3-8.
24. Ettenberg SA, Magnifico A, Cuello M, et al. Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem 2001; 276: 27677-84.
25. Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-7.
26. Teis D, Wunderlich W, Huber LA. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev Cell 2002; 3: 803-14.
27. Palamidessi A, Frittoli E, Garré M et al. Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell 2008; 134: 135-47.
28. Schenck A, Goto-Silva L, Collinet C et al. The endosomal protein App l1 mediates Akt substrate specificity and cell survival in vertebrate development. Cell 2008; 133: 486-97.
29. Le Roy C, Wrana JL. Signaling and endocytosis: a team effort for cell migration. Dev Cell 2005; 9: 167-8.
30. Polo S, Di Fiore PP. Endocytosis conducts the cell signaling orchestra. Cell 2006; 124: 897-900.
31. Rao DS, Bradley SV, Kumar PD et al. Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells. Cancer Cell 2003; 3: 471-82.
32. Joffre C, Barrow R, Ménard L, Calleja V, Hart IR, Kermorgant S. A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol 2011; 13: 827-37.